PSMA-RLT in Biochemically Recurrent PCa

Prospective single-center one-arm phase II study in patients with prostate cancer and confirmed biochemical recurrence (BCR) with PSA of ≥ 0.2 ng/ml after radical prostatectomy (RP) or PSA \> nadir + 2ng/ml after radiotherapy (RT) but not radio-morphological local recurrence after primary therapy with curative intent receive systemic therapy with only 2 cycles of highly standardized (3 GBq in first cycle and 6 GBq in the second cycle) PSMA-RLT at 6-week intervals.

Trial Details

NCT ID
NCT06220188
Phase
PHASE2
Sponsor
Medical University of Vienna
Status
RECRUITING
Cancer Type
Prostate Cancer
Interventions
  • [177Lu]Lu-PSMA I&T
Locations (sample)
  • Vienna, Austria|48.20849,16.37208

Key Eligibility Criteria

  • Patients with biochemical recurrence after radical prostatectomy and radiotherapy with a PSA doubling-time (DT) of ≤ 12 months.
  • No hormonal therapy within the last 12 months or recovered testosterone levels.
  • PSMA PET negative result for local recurrence; presence of distant metastases is allowed: (cN0, cM0/cM1).
  • Eastern Cooperative Oncology Group (ECOG) Performance Status: 0-1

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Prostate Cancer Trials on Trialify →